Back to Details

tooluniverse-aging-senescence

Compare original and translation side by side

🇺🇸

Original

English
🇨🇳

Translation

Chinese

Aging & Cellular Senescence Research

衰老与细胞衰老研究

Aging Research Reasoning

衰老研究推理逻辑

Before querying any tool, ask the central question: is this a cause or consequence of aging?
Senescence markers (SA-β-gal, p16/CDKN2A, SASP factors like IL-6 and IL-8) indicate that senescent cells are present. But their presence does not prove that senescence is driving the phenotype. Correlation is easy to establish. Causation requires an intervention. If senolytic drugs (dasatinib+quercetin, fisetin, navitoclax) clear senescent cells and the age-related phenotype improves, that is causal evidence. If clearing senescent cells has no effect, something else is driving the pathology.
Apply this reasoning when interpreting any gene or pathway query: classify it first by hallmark, then ask whether the evidence for its role is correlative (expression data, GWAS association) or causal (functional assay, genetic knockout, senolytic intervention).
Evidence grade the findings: T1 is human genetic evidence (GWAS, centenarian studies). T2 is model organism lifespan data. T3 is cell culture senescence data. T4 is computational prediction. Do not conflate T3 cell culture data with T1 human evidence — they are very different levels of confidence.
A final principle: cellular senescence is one hallmark of aging, not aging itself. Distinguish senescence from organismal aging, from age-related disease, and from progeria (accelerated aging syndromes). These require different tools and different interpretations.
在调用任何工具前，先思考核心问题：这是衰老的原因还是结果？
衰老标志物（SA-β-gal、p16/CDKN2A、IL-6和IL-8等SASP因子）表明衰老细胞的存在，但它们的存在无法证明衰老正在驱动表型。相关性很容易确立，但因果关系需要干预验证。如果溶衰老药物（达沙替尼+槲皮素、非瑟酮、Navitoclax）清除衰老细胞后，年龄相关表型得到改善，这就是因果证据。如果清除衰老细胞没有效果，那么是其他因素在驱动病理变化。
解读任何基因或通路查询时都要应用这一逻辑：先按衰老标志分类，再判断其作用的证据是相关性（表达数据、GWAS关联）还是因果性（功能实验、基因敲除、溶衰老干预）。
对研究结果进行证据分级：T1为人类遗传证据（GWAS、百岁老人研究）；T2为模式生物寿命数据；T3为细胞培养衰老数据；T4为计算预测。不要混淆T3细胞培养数据和T1人类证据——它们的置信水平差异很大。
最后一个原则：细胞衰老是衰老的标志之一，而非衰老本身。要区分细胞衰老与机体衰老、年龄相关疾病以及早老症（加速衰老综合征）。这些需要不同的工具和解读方式。

LOOK UP, DON'T GUESS

查资料，勿猜测

When uncertain about any scientific fact, SEARCH databases first (PubMed, UniProt, ChEMBL, ClinVar, etc.) rather than reasoning from memory. A database-verified answer is always more reliable than a guess.
当对任何科学事实不确定时，先搜索数据库（PubMed、UniProt、ChEMBL、ClinVar等），而非凭记忆推理。经数据库验证的答案永远比猜测更可靠。

When to Use

使用场景

  • "What genes are associated with longevity?"
  • "Find senolytic drug candidates for [disease]"
  • "What are the markers of cellular senescence?"
  • "How does [gene] relate to aging?"
  • "GWAS hits for age-related diseases"
  • "Pathways involved in cellular senescence"
  • "What drugs target senescent cells?"
Not this skill: For rare disease genetics, use 
tooluniverse-rare-disease-diagnosis
. For general disease research, use 
tooluniverse-disease-research
.
  • "哪些基因与长寿相关？"
  • "为[疾病]寻找溶衰老药物候选物"
  • "细胞衰老的标志物有哪些？"
  • "[基因]与衰老有何关联？"
  • "年龄相关疾病的GWAS位点"
  • "参与细胞衰老的通路"
  • "哪些药物靶向衰老细胞？"
非本技能适用场景：罕见病遗传学研究，请使用
tooluniverse-rare-disease-diagnosis
；通用疾病研究，请使用
tooluniverse-disease-research
。

Workflow

工作流程

Phase 0: Query Parsing — aging gene, senescence marker, age-related disease, or drug query
    |
Phase 1: Hallmarks Classification — map to the 12 hallmarks of aging framework
    |
Phase 2: Genetic Evidence — GWAS, longevity loci, model organism data
    |
Phase 3: Pathway Analysis — senescence, autophagy, telomere, epigenetic pathways
    |
Phase 4: Senolytic/Geroprotector Drug Discovery — existing drugs, clinical trials
    |
Phase 5: Literature & Clinical Context — published evidence, ongoing trials
    |
Phase 6: Interpretation & Report — evidence-graded findings with translational potential
Phase 0: 查询解析 — 衰老基因、衰老标志物、年龄相关疾病或药物类查询
    |
Phase 1: 标志分类 — 映射至12项衰老标志框架
    |
Phase 2: 遗传证据 — GWAS、长寿位点、模式生物数据
    |
Phase 3: 通路分析 — 衰老、自噬、端粒、表观遗传通路
    |
Phase 4: 溶衰老/抗衰老药物发现 — 现有药物、临床试验
    |
Phase 5: 文献与临床背景 — 已发表证据、正在进行的试验
    |
Phase 6: 解读与报告 — 带转化潜力的证据分级研究结果

Phase 1: Hallmarks Classification

Phase 1: 标志分类

Organize findings around the 12 hallmarks of aging (Lopez-Otin et al., Cell 2023). When a user asks about an aging gene, first classify which hallmark(s) it belongs to, then investigate that hallmark's pathway and disease connections. This prevents scattershot querying — each hallmark has specific pathways and tool strategies.
The hallmarks most amenable to ToolUniverse investigation are: genomic instability (DNA repair genes: ATM, ATR, BRCA1/2, TP53), telomere attrition (TERT, TERC, POT1), epigenetic alterations (DNMT1/3, TET1-3, SIRT1-7), loss of proteostasis (autophagy pathway hsa04140), deregulated nutrient sensing (mTOR pathway hsa04150, FOXO pathway hsa04068, AMPK, IGF1), mitochondrial dysfunction (PINK1, PARKIN, PGC1α), and cellular senescence (CDKN2A/p16, CDKN1A/p21, TP53, RB — KEGG pathway hsa04218).
For altered intercellular communication, focus on SASP factors: IL6, IL8, MCP1 (CCL2), MMP3, MMP9, PAI1, IGFBP7, VEGF. These are the secreted signals that make senescent cells pathological for surrounding tissue.
围绕12项衰老标志（Lopez-Otin等人，Cell 2023）整理研究结果。当用户询问某一衰老基因时，先归类它属于哪些标志，再研究该标志的通路及疾病关联。这能避免零散查询——每个标志都有特定的通路和工具策略。
最适合用ToolUniverse研究的标志包括：基因组不稳定性（DNA修复基因：ATM、ATR、BRCA1/2、TP53）、端粒损耗（TERT、TERC、POT1）、表观遗传改变（DNMT1/3、TET1-3、SIRT1-7）、蛋白稳态丧失（自噬通路hsa04140）、营养感应失调（mTOR通路hsa04150、FOXO通路hsa04068、AMPK、IGF1）、线粒体功能障碍（PINK1、PARKIN、PGC1α）以及细胞衰老（CDKN2A/p16、CDKN1A/p21、TP53、RB——KEGG通路hsa04218）。
对于细胞间通讯改变，重点关注SASP因子：IL6、IL8、MCP1（CCL2）、MMP3、MMP9、PAI1、IGFBP7、VEGF。这些是使衰老细胞对周围组织产生病理影响的分泌信号。

Phase 2: Genetic Evidence

Phase 2: 遗传证据

The best human evidence for aging genes comes from longevity GWAS and centenarian studies. Well-established loci include: APOE (19q13.32, strongest longevity signal), FOXO3 (5q33.3, replicated across multiple centenarian cohorts), TERT (10q24, telomere length GWAS), and CDKN2A/B (9p21.3, GWAS for CVD, cancer, and T2D — all age-related diseases sharing this locus).
Important caveat: many FOXO3 longevity studies (Willcox 2008, Flachsbart 2009) used targeted genotyping rather than GWAS arrays, so they do not appear in the GWAS Catalog. Always supplement GWAS Catalog queries with PubMed literature searches for centenarian studies.
python
undefined
衰老基因的最佳人类证据来自长寿GWAS和百岁老人研究。已确立的位点包括：APOE（19q13.32，最强长寿信号）、FOXO3（5q33.3，在多个百岁老人队列中重复验证）、TERT（10q24，端粒长度GWAS）以及CDKN2A/B（9p21.3，CVD、癌症和2型糖尿病的GWAS位点——这些年龄相关疾病共享该位点）。
重要提示：许多FOXO3长寿研究（Willcox 2008、Flachsbart 2009）采用的是靶向基因分型而非GWAS芯片，因此不会出现在GWAS Catalog中。务必结合PubMed文献搜索补充百岁老人研究的信息。
python
undefined

Best for gene-centric analysis

最适合基因中心分析

gwas_get_snps_for_gene(gene_symbol="FOXO3")
gwas_get_snps_for_gene(gene_symbol="FOXO3")

For trait queries — note "longevity" is not a standard EFO term; try "lifespan" or specific diseases

用于性状查询——注意"longevity"不是标准EFO术语；尝试"lifespan"或特定疾病

gwas_search_associations(query="telomere length")
gwas_search_associations(query="telomere length")

OpenTargets aggregated evidence

OpenTargets整合证据

OpenTargets_get_associated_targets_by_disease_efoId(efoId="EFO_0004847", limit=20)
OpenTargets_get_associated_targets_by_disease_efoId(efoId="EFO_0004847", limit=20)

Essential for centenarian studies not in GWAS Catalog

对GWAS Catalog中未收录的百岁老人研究至关重要

PubMed_search_articles(query="FOXO3 GWAS longevity centenarian meta-analysis")

---
PubMed_search_articles(query="FOXO3 GWAS longevity centenarian meta-analysis")

---

Phase 3: Pathway Analysis

Phase 3: 通路分析

The central senescence pathway is KEGG hsa04218. Start there when investigating any senescence-related gene. Supporting pathways: autophagy (hsa04140, implicated in senescence clearance and proteostasis), mTOR signaling (hsa04150, rapamycin target), FOXO signaling (hsa04068, stress resistance and autophagy), and p53 signaling (hsa04115, DNA damage response).
python
KEGG_get_pathway_genes(pathway_id="hsa04218")   # Cellular senescence
kegg_search_pathway(keyword="autophagy")          # hsa04140
kegg_search_pathway(keyword="mTOR signaling")     # hsa04150
kegg_search_pathway(keyword="FOXO signaling")     # hsa04068
kegg_search_pathway(keyword="p53 signaling")      # hsa04115
For SASP network analysis, STRING and Reactome are the right tools:
python
sasp_genes = ["IL6", "IL8", "MCP1", "MMP3", "MMP9", "PAI1", "IGFBP7", "VEGF", "CCL2"]
STRING_get_network(identifiers="\r".join(sasp_genes), species=9606)
ReactomeAnalysis_pathway_enrichment(identifiers=" ".join(sasp_genes))
核心衰老通路是KEGG hsa04218。研究任何衰老相关基因时都从这里开始。支持通路包括：自噬（hsa04140，与衰老细胞清除和蛋白稳态相关）、mTOR信号通路（hsa04150，雷帕霉素靶点）、FOXO信号通路（hsa04068，应激抵抗与自噬）以及p53信号通路（hsa04115，DNA损伤应答）。
python
KEGG_get_pathway_genes(pathway_id="hsa04218")   # 细胞衰老
kegg_search_pathway(keyword="autophagy")          # hsa04140
kegg_search_pathway(keyword="mTOR signaling")     # hsa04150
kegg_search_pathway(keyword="FOXO signaling")     # hsa04068
kegg_search_pathway(keyword="p53 signaling")      # hsa04115
对于SASP网络分析，STRING和Reactome是合适的工具：
python
sasp_genes = ["IL6", "IL8", "MCP1", "MMP3", "MMP9", "PAI1", "IGFBP7", "VEGF", "CCL2"]
STRING_get_network(identifiers="\r".join(sasp_genes), species=9606)
ReactomeAnalysis_pathway_enrichment(identifiers=" ".join(sasp_genes))

Interpreting Senescence Markers

衰老标志物解读

Markers must be interpreted together, not individually. p16 (CDKN2A) upregulation is the closest to a gold standard — it marks irreversible cell cycle arrest — but it is also elevated in some cancers. p21 (CDKN1A) can reflect either transient quiescence or permanent senescence, so it is not specific. SA-β-gal is a lysosomal activity assay that can give false positives in high-confluence cultures. SASP factors (IL-6, IL-8) are also elevated in infection and autoimmunity. γH2AX foci are transient in normal DNA damage but persistent in senescence. Telomere shortening is only relevant for replicative senescence, not for oncogene-induced senescence.
Use a panel. A cell with p16↑ + SA-β-gal↑ + SASP↑ + γH2AX↑ is senescent. A cell with only one marker may not be.
标志物必须结合起来解读，不能单独使用。p16（CDKN2A）上调最接近金标准——它标志着不可逆的细胞周期停滞，但在某些癌症中也会升高。p21（CDKN1A）可能反映短暂静止或永久衰老，因此不具有特异性。SA-β-gal是溶酶体活性检测，在高密度培养中可能出现假阳性。SASP因子（IL-6、IL-8）在感染和自身免疫中也会升高。γH2AX灶在正常DNA损伤中是短暂的，但在衰老中会持续存在。端粒缩短仅与复制性衰老相关，与癌基因诱导的衰老无关。
使用标志物组合。p16↑ + SA-β-gal↑ + SASP↑ + γH2AX↑的细胞才是衰老细胞。仅具备一种标志物的细胞可能不是衰老细胞。

Phase 4: Senolytic and Geroprotector Drug Discovery

Phase 4: 溶衰老与抗衰老药物发现

Senolytics selectively kill senescent cells. The most clinically advanced combination is dasatinib + quercetin (D+Q), currently in Phase II trials for idiopathic pulmonary fibrosis and diabetic kidney disease. Navitoclax (BCL-2/BCL-XL inhibitor) has strong preclinical data but causes thrombocytopenia, limiting clinical use. Fisetin has Phase II trials for frailty. UBX0101 failed Phase II for osteoarthritis.
Geroprotectors slow aging rather than removing senescent cells. Rapamycin (mTOR inhibitor) extends mouse lifespan and is FDA-approved for transplant. Metformin (AMPK activator) is being tested in the TAME trial. NAD+ precursors (NMN, NR) are in Phase II trials.
python
DGIdb_get_drug_gene_interactions(genes=["BCL2", "BCL2L1", "TP53", "CDKN2A"])
search_clinical_trials(condition="senescence", query_term="senolytic")
search_clinical_trials(condition="aging", query_term="dasatinib quercetin")
ChEMBL_search_drugs(query="navitoclax")
When evaluating a drug candidate, always check clinical status: preclinical data in mice does not translate reliably to humans (telomere biology differs substantially between species). Prioritize T1 human evidence.
溶衰老物质选择性杀死衰老细胞。临床进展最领先的组合是达沙替尼+槲皮素（D+Q），目前正处于特发性肺纤维化和糖尿病肾病的II期试验阶段。Navitoclax（BCL-2/BCL-XL抑制剂）有很强的临床前数据，但会导致血小板减少，限制了临床应用。非瑟酮正在进行衰弱症的II期试验。UBX0101在骨关节炎的II期试验中失败。
抗衰老物质可延缓衰老而非清除衰老细胞。雷帕霉素（mTOR抑制剂）可延长小鼠寿命，且已获FDA批准用于移植。二甲双胍（AMPK激活剂）正在TAME试验中测试。NAD+前体（NMN、NR）处于II期试验阶段。
python
DGIdb_get_drug_gene_interactions(genes=["BCL2", "BCL2L1", "TP53", "CDKN2A"])
search_clinical_trials(condition="senescence", query_term="senolytic")
search_clinical_trials(condition="aging", query_term="dasatinib quercetin")
ChEMBL_search_drugs(query="navitoclax")
评估药物候选物时，务必检查临床状态：小鼠的临床前数据无法可靠转化为人类数据（物种间端粒生物学差异显著）。优先考虑T1人类证据。

Phase 5: Literature and Clinical Context

Phase 5: 文献与临床背景

python
PubMed_search_articles(query="cellular senescence senolytics clinical trial", max_results=20)
search_clinical_trials(condition="cellular senescence")
search_clinical_trials(query_term="rapamycin aging")
python
PubMed_search_articles(query="cellular senescence senolytics clinical trial", max_results=20)
search_clinical_trials(condition="cellular senescence")
search_clinical_trials(query_term="rapamycin aging")

Phase 6: Report Structure

Phase 6: 报告结构

  1. Hallmarks Classification — which hallmarks are relevant and why
  2. Genetic Evidence — GWAS loci, longevity genes, evidence grade (T1-T4)
  3. Pathway Analysis — relevant pathways with key genes
  4. Senescence Markers — expression evidence with interpretation caveats
  5. Drug Candidates — senolytics and geroprotectors with evidence grade and clinical status
  6. Clinical Trials — ongoing trials
  7. Mechanistic Model — how the gene/pathway contributes to aging (cause or consequence?)
  8. Research Gaps — what interventional data would resolve the causal question
  1. 标志分类 — 相关标志及原因
  2. 遗传证据 — GWAS位点、长寿基因、证据分级（T1-T4）
  3. 通路分析 — 相关通路及关键基因
  4. 衰老标志物 — 表达证据及解读注意事项
  5. 药物候选物 — 溶衰老与抗衰老物质的证据分级及临床状态
  6. 临床试验 — 正在进行的试验
  7. 机制模型 — 基因/通路如何促成衰老（原因还是结果？）
  8. 研究空白 — 哪些干预数据可解决因果问题

Age-Dependent Expression Analysis

年龄依赖性表达分析

GTEx provides tissue-level median expression but not directly age-stratified data. For age-dependent expression analysis, search PubMed for published GTEx age studies, or use GEO datasets with age metadata.
python
undefined
GTEx提供组织水平的中位表达数据，但不直接提供年龄分层数据。如需进行年龄依赖性表达分析，请搜索PubMed上已发表的GTEx年龄研究，或使用带年龄元数据的GEO数据集。
python
undefined

GTEx tissue expression (not age-stratified directly)

GTEx组织表达（非直接年龄分层）

GTEx_get_median_gene_expression(gene_symbol="CDKN2A")
GTEx_get_median_gene_expression(gene_symbol="CDKN2A")

Search for published age-expression analyses

搜索已发表的年龄表达分析

PubMed_search_articles(query="GTEx age-dependent expression CDKN2A")

---
PubMed_search_articles(query="GTEx age-dependent expression CDKN2A")

---

Limitations

局限性

  • Aging is multifactorial — no single gene or pathway explains it; this skill investigates specific aspects
  • Mouse lifespan data does not reliably translate to humans (different telomere biology, metabolic rate)
  • No single senescence marker is definitive; use a panel (p16 + SA-β-gal + SASP + γH2AX)
  • No FDA-approved senolytic exists yet; most trials are Phase I/II
  • Epigenetic clocks (Horvath/Hannum) require methylation array data processing not directly queryable via ToolUniverse
  • 衰老具有多因素性——没有单一基因或通路能解释衰老；本技能仅研究特定方面
  • 小鼠寿命数据无法可靠转化为人类数据（端粒生物学、代谢率存在差异）
  • 没有单一衰老标志物是确定的；需使用组合标志物（p16 + SA-β-gal + SASP + γH2AX）
  • 目前尚无FDA批准的溶衰老药物；大多数试验处于I/II期
  • 表观遗传时钟（Horvath/Hannum）需要甲基化芯片数据处理，无法通过ToolUniverse直接查询